Optimized Cas9 expression improves performance of large-scale CRISPR screening

Autor: René Bernards, van der Ven D, Katarzyna Jastrzebski, Heimans H, Ben Morris, Fernandes Neto Jm, Matheus H. Dias, Lenno Krenning, René H. Medema, Cor Lieftink, Roderick L. Beijersbergen

CRISPR technology is an invaluable tool for large-scale functional genomic screening. Genome editing efficiency and timing are important parameters impacting the performance of pooled CRISPR screens. Here we show that by optimizing Cas9 expression le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e999ad610bdd846aaa0af3eaebbd4f9c
https://doi.org/10.1101/2021.07.13.452178

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

Autor: Dias MH; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Friskes A; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wang S; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Fernandes Neto JM; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Gemert F; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mourragui S; Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center, Utrecht, the Netherlands., Papagianni C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kuiken HJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mainardi S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Alvarez-Villanueva D; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., Lieftink C; Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Morris B; Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Dekker A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Dijk E; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wilms LHS; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., da Silva MS; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.; Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, SP, Brazil., Jansen RA; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Mulero-Sánchez A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Malzer E; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Vidal A; Department of Pathology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain., Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, Barcelona, Spain., Salazar R; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, Barcelona, Spain., Wailemann RAM; Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil., Torres TEP; Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil.; Department of Clinical and Experimental Oncology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil., De Conti G; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Raaijmakers JA; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; University of Iceland, Faculty of Medicine, Reykjavik, Iceland., Yuan S; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China., Qin W; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Kovach JS; Lixte Biotechnology Holdings, Inc., Pasadena, California., Armelin HA; Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil., Te Riele H; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Oudenaarden A; Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center, Utrecht, the Netherlands., Jin H; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Beijersbergen RL; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain., Medema RH; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Jul 01; Vol. 14 (7), pp. 1276-1301.

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

Autor: Fernandes Neto JM; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Nadal E; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain., Bosdriesz E; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Computer Science, Faculty of Science, Vrije Universiteit, Amsterdam, The Netherlands., Ooft SN; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Farre L; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.; Institute Gonçalo Moniz, Fundaçao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brasil., McLean C; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Klarenbeek S; Experimental Animal Pathology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Jurgens A; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Hagen H; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Wang L; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Autonomous University of Barcelona (UAB), Barcelona, Spain., Martinez-Marti A; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Autonomous University of Barcelona (UAB), Barcelona, Spain., Vidal A; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain., Voest E; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Wessels LFA; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., van Tellingen O; Division of Clinical Pharmacology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands., Villanueva A; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain., Bernards R; Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. r.bernards@nki.nl.

Publikováno v: Nature communications [Nat Commun] 2020 Jun 22; Vol. 11 (1), pp. 3157. Date of Electronic Publication: 2020 Jun 22.

[Evaluation of circulation dynamics in muscles. II. Simultaneous muscle clearance of sodium-24 and xenon-133].

Autor: Kauffman P, Camargo EE, Fernandes Neto JM, Rockman RL, Dias Neto AL, Carvalho N, Wolosker M, Puech Leão LE

Publikováno v: Revista do Hospital das Clinicas [Rev Hosp Clin Fac Med Sao Paulo] 1975 Nov-Dec; Vol. 30 (6), pp. 495-8.

[Quantification of arteriovenous shunts of the lower extremities].

Autor: Kauffman P, Fernandes Neto JM, Dias Neto AL, Camargo EE, Langer B, Leão LE

Publikováno v: Revista do Hospital das Clinicas [Rev Hosp Clin Fac Med Sao Paulo] 1983 Sep-Oct; Vol. 38 (5), pp. 195-9.